Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generic, Specialty and AvKARE Segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The AvKARE segment focuses on pharmaceuticals, medical and surgical products, and services primarily to governmental agencies. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amneal Pharmaceuticals reports strong Q4 earnings and outlines growth strategies

Amneal Pharmaceuticals delivered strong Q4 2022 results with revenue of $610 million and adjusted EBITDA of $154 million, expecting stable performance in 2023 with total revenue of $2.25-2.35 billion.
The company's strategic focus on complex, high-growth products, international expansion, and new product launches positions it for growth opportunities despite challenges in generic growth rates and competitive pressures.
With a robust biosimilars growth plan, unique pricing strategies, and market expansion initiatives, Amneal Pharmaceuticals aims to capture market share, drive revenue growth, and sustain its performance in the pharmaceutical industry.
Despite facing challenges such as potential competition and manufacturing delays, Amneal Pharmaceuticals remains optimistic about its growth prospects, emphasizing long-term strategies for revenue expansion and market positioning.

Amneal Pharmaceuticals reports strong Q1 results and eyes strategic growth

Amneal Pharmaceuticals' Q1 2023 performance reflects strategic growth initiatives across all segments, positioning the company for future success.
While challenges like debt reduction and refinancing exist, the company's strengths in product diversification and market adoption offer growth potential.
Opportunities in Injectables, Biosimilars, and capital allocation strategies provide avenues for revenue growth and operational excellence.

Amneal Pharmaceuticals reports strong Q2 earnings, eyes sustainable growth

Amneal Pharmaceuticals is on track for sustainable growth and EBITDA acceleration.
The company is well-positioned to capitalize on the growth potential in biosimilars and complex generics.
With a focus on organic growth and new product launches, Amneal aims to drive revenue and expand market share.

Amneal Pharmaceuticals excels in Q3, eyes international expansion and specialty growth

Amneal Pharmaceuticals reported strong financials, raised guidance, and highlighted growth in key segments. The company's strategic focus on operational efficiency, supply chain expansion, and international growth positions it for sustained success. Challenges include managing expenses and liabilities, but opportunities in new markets and product segments offer avenues for growth.

Amneal Pharmaceuticals posts record revenue in Q4 2023, eyes biosimilar growth

Amneal Pharmaceuticals reported robust financials for Q4 2023 and full-year 2023, with record revenue and EBITDA figures. The company's strategic focus on biosimilars, portfolio expansion, and growth initiatives underpin its optimistic outlook for 2024. Despite industry challenges, Amneal remains committed to innovation, affordability, and addressing pricing issues.

Amneal Pharmaceuticals reports record Q1 revenues and eyes biosimilar growth

Amneal Pharmaceuticals' Q1 performance reflects robust growth across all segments, underpinned by strong financial execution and a sustainable growth profile.
The company's strengths lie in its market position, diverse portfolio, commitment to quality, and strategic partnerships, positioning them for continued success.
While facing challenges related to product approvals and revenue uncertainties, Amneal is well-positioned to capitalize on opportunities in biosimilars, strategic partnerships, and market expansion.

Amneal Pharmaceuticals excels in Q2, eyes international expansion for growth

Amneal Pharmaceuticals delivered a strong performance in Q2 2024, with robust revenue growth and raised guidance, signaling confidence in future prospects.
The company's strategic strengths lie in international expansion, diversified revenue streams, and a focus on financial stability through debt reduction and investments.
Challenges include maintaining growth momentum, effective execution of expansion plans, and balancing debt reduction with growth investments.
Opportunities abound in new product approvals, market expansion, and innovation, positioning Amneal Pharmaceuticals for sustained growth and market leadership.

Amneal Pharmaceuticals reports robust Q3 results and eyes future growth

Amneal Pharmaceuticals' Q3 performance reflects strong revenue growth and strategic product initiatives in key therapeutic areas.
The company's focus on affordable medicines, biosimilars, and strategic investments underscores its commitment to future growth.
While facing challenges in market competition and operational optimization, Amneal is well-positioned to leverage growth opportunities.
With a solid financial performance and a focus on sustainable value creation, Amneal is poised for long-term success in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Amneal (AMRX) suffers a setback as the FDA issues a complete response letter (CRL) to its new drug application (NDA) for IPX203 for treating Parkinson's disease.

Amneal (AMRX) Shares Down on CRL for Parkinson's Disease Drug

The U.S. Food and Drug Administration (FDA) has declined to approve Amneal Pharmaceuticals' drug for Parkinson's disease due to inadequate safety data on the treatment to help control symptoms in patients for a longer duration, the company said on Monday.

US FDA declines to approve Amneal Pharma's Parkinson's drug

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the launch of its authorized generic for Xyrem®1 (Sodium Oxybate) oral solution CIII in the United States. Sodium Oxybate oral solution, 0.5 g/mL is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy. In addition, the Company announced it has received Abbr.

Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for IPX203 for the treatment of Parkinson's disease. The letter indicated that although an adequate scientific bridge was established for the safety of one ingredient, levodopa (LD), based on pharmacokinetic studies, it was not.

Amneal Receives U.S. FDA Complete Response Letter for IPX203

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the release of its third annual (2022) Environmental, Social and Governance (ESG) Report. This 2022 report provides a look at our progress across our ESG focus areas, including updates to our people data and sustainability programs. New this year, the report is mapped to the United Nations Sustainable Development Goals (UN SDGs) and highlights our contributions in support of.

Amneal Releases 2022 Environmental, Social and Governance Report Mapped to the United Nations Sustainable Development Goals

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the 505(b)(2) New Drug Application (NDA) approval from the U.S. Food and Drug Administration (“FDA”) for PEMRYDI RTU®. This product is the first and only ready-to-use presentation of pemetrexed for injection and does not require reconstitution, dilution, or refrigeration. This injectable will be available in three vial sizes: 100mg/10mL; 500 mg/50mL; and 1,000mg/100mL. The C.

Amneal Receives 505(b)(2) NDA Approval from FDA for PEMRYDI RTU®, a Ready-to-Use Oncology Injectable

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 2023 Jefferies Healthcare Conference held on June 7, 2023 in New York City. Mr. Patel will also be hosting a presentation at 2:30 PM Eastern Time and a live webcast will be accessible through the Investor Relations section of the Company's website at https:/.

Amneal to Participate at the 2023 Jefferies Healthcare Conference

Groupon

Lilium BV

Sidus Space

Penny stocks to watch under $5. The post Best Penny Stocks To Buy Now?

Best Penny Stocks To Buy Now? 4 to Watch Under $5 This Week

Fortuna Silver Mines

OncoSec Medical

Hot penny stocks with big news this week. The post 3 Top Penny Stocks To Watch After Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Penny Stocks To Watch After Big News This Week

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of FYLNETRA™ (pegfilgrastim-pbbk), a biosimilar referencing Neulasta® in a pre-filled single-dose syringe. FYLNETRA™ is used to treat neutropenia (low neutrophils which are a type of white blood cells that fight infection) which is commonly experienced by patients undergoing chemotherapy. This product was developed in collaboration with Kashiv Bioscienc.

Amneal Launches Third Biosimilar with FYLNETRA™ (pegfilgrastim-pbbk) in the United States

Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q1 2023 Earnings Conference Call May 5, 2023 8:30 AM ET Company Participants Tony DiMeo - Head-Investor Relations Chirag Patel - President & Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President, Chief Financial Officer Conference Call Participants Balaji Prasad - Barclays Chris Schott - JPMorgan David Amsellem - Piper Sandler Greg Fraser - Truist Securities Operator Hello, everyone and welcome to the Amneal Pharmaceuticals First Quarter 2023 Earnings Conference Call. My name is Emily, and I'll be your moderator for today's call.

Amneal Pharmaceuticals, Inc. (AMRX) Q1 2023 Earnings Call Transcript

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its actual results today for the first quarter ended March 31, 2023. “We are very pleased with our strong first quarter results and start to 2023. We are confident in our continued momentum driven by the broad-based strength of our diverse and increasingly complex generics portfolio, uptake of our new biosimilars, expansion of our AvKARE business, and the continued growth and pote.

Amneal Reports First Quarter 2023 Financial Results

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate at the 22nd Annual Needham Virtual Healthcare Conference held on April 19, 2023. Mr.

Amneal to Participate at the 22nd Annual Needham Virtual Healthcare Conference

Amneal Pharmaceuticals Inc.'s stock AMRX, -2.16% soared 14% in premarket trade Monday, after the generics and specialty pharmaceuticals company offered first-quarter guidance that topped consensus estimates. Bridgewater, N.J.

Amneal Pharmaceuticals' stock soars 14% premarket after company offers upbeat Q1 guidance

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced certain unaudited preliminary financial results for the first quarter ended March 31, 2023. The Company is also affirming financial guidance for the year ending December 31, 2023, which was previously issued on March 2, 2023. The Company plans to report actual first quarter 2023 financial results on May 5, 2023.

Amneal Reports Certain Preliminary First Quarter 2023 Financial Results and Affirms Full Year 2023 Financial Guidance

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2023 financial results on Friday May 5, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on May 5, 2023. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com.

Amneal to Report First Quarter 2023 Results on May 5, 2023

Amneal Pharmaceuticals, Inc. (NYSE:AMRX ) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ET Company Participants Anthony DiMeo - Senior Director of Investor Relations Chirag Patel - President and Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President, Chief Financial Officer Harsher Singh - Senior Vice President, Biosciences Conference Call Participants Elliot Wilbur - Raymond James Gary Nachman - BMO Capital Markets Chris Schott - JPMorgan David Amsellem - Piper Sandler Balaji Prasad - Barclays Greg Fraser - Truist Securities Operator Hello, everyone. And welcome to the Amneal Fourth Quarter 2022 Earnings Conference Call.

Amneal Pharmaceuticals, Inc. (AMRX) Q4 2022 Earnings Call Transcript

Amneal (AMRX) delivered earnings and revenue surprises of 9.52% and 4.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Amneal Pharmaceuticals (AMRX) Beats Q4 Earnings and Revenue Estimates

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for naloxone hydrochloride nasal spray, USP, 4mg, which is the generic version of Narcan® and is used in the treatment of a known or suspected opioid overdose emergency.

Amneal Announces U.S. FDA Filing Acceptance of Abbreviated New Drug Application for Naloxone Hydrochloride Nasal Spray, USP, 4mg

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced its results today for the fourth quarter and full year ended December 31, 2022. “2022 was a year of solid execution and very good progress in advancing key strategic priorities marked by a robust cadence of new innovations in Generics, scaling our injectables portfolio, advancing our Specialty pipeline and entering the U.S. biosimilars market.

Amneal Reports Fourth Quarter and Full Year 2022 Financial Results

Atossa Genetics

Selecta Biosciences

Troika Media Group

Penny stocks under $3 to watch this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 4 Stocks Under $3 To Watch This Week

BRIDGEWATER, N.J.--( BUSINESS WIRE )--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2022 financial results on Thursday March 2, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2023.

Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023

Intercept Pharma

Intercept reached a settlement with Amneal that delays a generic version of its only product. In response, ICPT stock surged Wednesday.

Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years

ORION CORPORATION PRESS RELEASE 4 JANUARY 2023 at 16.00 EET

Orion and Amneal enter strategic partnership – Orion receives exclusive licence to commercialise Amneal's generic products in Europe, Australia and New Zealand

News for Amneal Pharmaceuticals Stock (AMRX)